These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

157 related articles for article (PubMed ID: 33076610)

  • 1. [Analysis on post-marketing effectiveness and immunogenicity of enterovirus-A71 vaccine].
    Hua RJ; Huang J; Zhang XJ; Shen Q; Cai MY; Yuan F; Zhang Y; Cui PF; Li Y; Shi HY; Xu B
    Zhonghua Liu Xing Bing Xue Za Zhi; 2020 Sep; 41(9):1518-1521. PubMed ID: 33076610
    [No Abstract]   [Full Text] [Related]  

  • 2. Enterovirus A71 vaccine effectiveness in preventing enterovirus A71 infection among medically-attended hand, foot, and mouth disease cases, Beijing, China.
    Wang X; An Z; Huo D; Jia L; Li J; Yang Y; Liang Z; Wang Q; Wang H
    Hum Vaccin Immunother; 2019; 15(5):1183-1190. PubMed ID: 30779680
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effectiveness of EV-A71 vaccination in prevention of paediatric hand, foot, and mouth disease associated with EV-A71 virus infection requiring hospitalisation in Henan, China, 2017-18: a test-negative case-control study.
    Li Y; Zhou Y; Cheng Y; Wu P; Zhou C; Cui P; Song C; Liang L; Wang F; Qiu Q; Guo C; Zeng M; Long L; Cowling BJ; Yu H
    Lancet Child Adolesc Health; 2019 Oct; 3(10):697-704. PubMed ID: 31375313
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effectiveness of enterovirus A71 vaccine in severe hand, foot, and mouth disease cases in Guangxi, China.
    Jiang L; Wang J; Zhang C; He W; Mo J; Zeng J; Chen M; Tan Y; Ning C
    Vaccine; 2020 Feb; 38(7):1804-1809. PubMed ID: 31892446
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Is a multivalent hand, foot, and mouth disease vaccine feasible?
    Klein M; Chong P
    Hum Vaccin Immunother; 2015; 11(11):2688-704. PubMed ID: 26009802
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Enterovirus A71 Containing Codon-Deoptimized VP1 and High-Fidelity Polymerase as Next-Generation Vaccine Candidate.
    Tsai YH; Huang SW; Hsieh WS; Cheng CK; Chang CF; Wang YF; Wang JR
    J Virol; 2019 Jul; 93(13):. PubMed ID: 30996087
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effectiveness of Enterovirus 71 inactivated vaccines against hand, foot, and mouth disease: A test-negative case-control study.
    Zhang Y; Cui J; Liu F; Song Y; Wang Q; Liu Y; Zhang Y; Li Z; Chang Z
    Hum Vaccin Immunother; 2024 Dec; 20(1):2330163. PubMed ID: 38544389
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Immunogenicity, safety, cross-reaction, and immune persistence of an inactivated enterovirus A71 vaccine in children aged from two months to 11 years in Taiwan.
    Huang LM; Chiu CH; Chiu NC; Lin CY; Li MT; Kuo TY; Weng YJ; Hsieh EF; Tai IC
    Vaccine; 2019 Mar; 37(13):1827-1835. PubMed ID: 30803843
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The stability and immunogenicity of formalin-inactivated Enterovirus A71 whole virion vaccine after ten years of low temperature storage.
    Shen YS; Chow YH; Fang CY; Wu SR; Chen CH; Huang MH; Liao CL; Chiang JR; Liu CC
    J Microbiol Immunol Infect; 2023 Dec; 56(6):1121-1128. PubMed ID: 37919172
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The changes in the epidemiology of hand, foot, and mouth disease after the introduction of the EV-A71 vaccine.
    Wang J; Jiang L; Zhang C; He W; Tan Y; Ning C
    Vaccine; 2021 Jun; 39(25):3319-3323. PubMed ID: 33994239
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The transfer and decay of maternal antibodies against enterovirus A71, and dynamics of antibodies due to later natural infections in Chinese infants: a longitudinal, paired mother-neonate cohort study.
    Wei X; Yang J; Gao L; Wang L; Liao Q; Qiu Q; Luo K; Yu S; Zhou Y; Liu F; Chen Q; Zhang J; Dai B; Yang H; Zhou J; Xing W; Chen X; He M; Ren L; Guo J; Luo L; Wu P; Chen Z; van Doorn HR; Cauchemez S; Cowling BJ; Yu H
    Lancet Infect Dis; 2021 Mar; 21(3):418-426. PubMed ID: 33031750
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Analysis on epidemiological characteristics of enterovirus 71 cases of hand-foot-mouth disease based on the active monitoring in Guangdong Province in 2011-2015].
    Xie DS; He JF; Yang F; Li H; Kang M; Zhang M; Ye X; Tan XH; Ni XH; Hu L; Sun LM
    Zhonghua Yu Fang Yi Xue Za Zhi; 2018 Jul; 52(7):738-742. PubMed ID: 29996302
    [No Abstract]   [Full Text] [Related]  

  • 13. EV-A71 vaccine licensure: a first step for multivalent enterovirus vaccine to control HFMD and other severe diseases.
    Mao Q; Wang Y; Bian L; Xu M; Liang Z
    Emerg Microbes Infect; 2016 Jul; 5(7):e75. PubMed ID: 27436364
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Clinically isolated enterovirus A71 subgenogroup C4 strain with lethal pathogenicity in 14-day-old mice and the application as an EV-A71 mouse infection model.
    Xu Y; Ma S; Zhu L; Huang Z; Chen L; Xu Y; Yin H; Peng T; Wang Y
    Antiviral Res; 2017 Jan; 137():67-75. PubMed ID: 27864074
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Comparison of Neutralizing Antibody Response Kinetics in Patients with Hand, Foot, and Mouth Disease Caused by Coxsackievirus A16 or Enterovirus A71: A Longitudinal Cohort Study of Chinese Children, 2017-2019.
    Zhou Y; Zhou J; Yang J; Qiu Q; Wang L; Yang J; Li Y; Liang L; Cui P; Cheng Y; Zheng W; Shi H; Gong H; Wang K; Zhou C; Chu JJH; Yu H
    J Immunol; 2022 Jul; 209(2):280-287. PubMed ID: 35777850
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Novel recombinant chimeric virus-like particle is immunogenic and protective against both enterovirus 71 and coxsackievirus A16 in mice.
    Zhao H; Li HY; Han JF; Deng YQ; Zhu SY; Li XF; Yang HQ; Li YX; Zhang Y; Qin ED; Chen R; Qin CF
    Sci Rep; 2015 Jan; 5():7878. PubMed ID: 25597595
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effectiveness of enterovirus A71 vaccine against pediatric HFMD and disease profile of post-vaccination infection.
    Duan X; Zhang L; Ding L; Zhang C; Chen Z; Cheng Y; Wang X; Peng H; Tang X; Ren X; Liao J; Yang S; Zhu Y; Luo W; Zeng Y; Yuan P; Long L
    Vaccine; 2024 Apr; 42(9):2317-2325. PubMed ID: 38433065
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Human Enterovirus 71 Protein Displayed on the Surface of Saccharomyces cerevisiae as an Oral Vaccine.
    Zhang C; Wang Y; Ma S; Li L; Chen L; Yan H; Peng T
    Viral Immunol; 2016 Jun; 29(5):288-95. PubMed ID: 27259043
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effect of difference between EV-A71 virus epidemic strain and "vaccine strain" on neutralizing antibody titer.
    Ding Y; Han Z
    Hum Vaccin Immunother; 2022 Nov; 18(6):2121565. PubMed ID: 36112355
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Post-marketing multi-center safety surveillance of inactivated enterovirus A71 vaccine (Vero cell)].
    Zeng J; Tang T; Wang YJ; Lyu HK; Huang JH; Li XQ; Jia NN; Zeng G; Chen ZP
    Zhonghua Yu Fang Yi Xue Za Zhi; 2019 Mar; 53(3):252-257. PubMed ID: 30841662
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 8.